Core Insights - Zenas BioPharma is advancing its obexelimab development program, with key clinical trials ongoing for autoimmune diseases, including the Phase 3 INDIGO trial for Immunoglobulin G4-Related Disease (IgG4-RD) and the Phase 2 MoonStone trial for Relapsing Multiple Sclerosis (RMS) [1][2][4] Clinical Trials - The Phase 3 INDIGO trial for IgG4-RD is the largest clinical trial conducted for this condition, with topline results expected around year-end 2025 [1][4] - Enrollment for the Phase 2 MoonStone trial in RMS has been completed, with results anticipated in early Q4 2025 [1][4] - The Phase 2 SunStone trial for Systemic Lupus Erythematosus (SLE) is expected to complete enrollment by year-end 2025, with topline results projected for mid-2026 [1][4] Financial Overview - As of June 30, 2025, Zenas BioPharma reported cash, cash equivalents, and investments totaling $274.9 million, which is expected to fund operations into Q4 2026 [1][4][16] - Research and development (R&D) expenses for Q2 2025 were $43.0 million, an increase from $33.8 million in Q2 2024, primarily due to higher clinical development costs for obexelimab [4][9] - General and administrative (G&A) expenses rose to $12.1 million in Q2 2025 from $5.9 million in Q2 2024, attributed to increased personnel costs and pre-commercialization activities [9][14] Product Information - Obexelimab is a bifunctional monoclonal antibody targeting CD19 and FcγRIIb, designed to inhibit B cell function without depleting them, potentially addressing chronic autoimmune diseases effectively [5][7] - The drug has shown pharmacologic activity in five completed clinical trials involving 198 subjects, indicating its potential as a potent B cell inhibitor [6]

Group 1 - Zenas BioPharma, Inc. (NASDAQ: ZBIO) is a biotech company based in Waltham, Massachusetts, which completed its IPO in September last year, raising $225 million by issuing approximately 13.24 million shares priced at $17 each [1] - The investing group Haggerston BioHealth provides insights for both novice and experienced biotech investors, including catalysts to watch for, buy and sell ratings, product sales forecasts, integrated financial statements, discounted cash flow analysis, and market-by-market analysis [1] - Edmund Ingham, a biotech consultant with over 5 years of experience, leads the Haggerston BioHealth investing group and has compiled detailed reports on over 1,000 companies in the biotech, healthcare, and pharma sectors [1]

Company Overview - Zenas BioPharma, Inc. is a clinical-stage global biopharmaceutical company focused on developing and commercializing therapies for autoimmune diseases [3] - The company's lead product candidate, obexelimab, is a bifunctional monoclonal antibody targeting CD19 and FcγRIIb, aimed at inhibiting the activity of B cells involved in autoimmune diseases without depleting them [3] - Zenas aims to leverage its experienced leadership and disciplined product acquisition strategy to identify and develop candidates that provide superior clinical benefits for patients with autoimmune diseases [3] Stock Option Grant - On June 16, 2025, Zenas granted a non-qualified stock option to purchase 112,000 shares of common stock to a newly hired employee as an inducement for employment [1] - The stock option has a ten-year term with an exercise price of $9.97, equal to the closing price on the grant date [2] - The option will vest over four years, with 25% vesting on the one-year anniversary of employment and the remainder vesting in 36 equal monthly installments, contingent on the employee's continued service [2]

Core Viewpoint - A class action lawsuit has been filed against Zenas BioPharma, Inc. for violations of federal securities laws related to misleading statements made during its IPO [1][4]. Group 1: Lawsuit Details - The lawsuit is initiated by the Schall Law Firm, which specializes in shareholder rights litigation [1][5]. - Investors who purchased Zenas securities during its IPO on September 13, 2024, are encouraged to contact the firm for participation in the lawsuit [2]. - The class has not yet been certified, meaning potential participants are not currently represented by an attorney [3]. Group 2: Allegations Against Zenas BioPharma - The complaint alleges that Zenas made false and misleading statements regarding its financial status, specifically overstating the runway of funded operations based on existing cash and expected IPO proceeds [4]. - The misleading public statements were made throughout the IPO period, leading to investor damages once the truth was revealed [4].

Core Viewpoint - The Gross Law Firm has issued a notice to shareholders of Zenas BioPharma, Inc. regarding a class action lawsuit related to misleading statements made during the company's initial public offering in September 2024 [1][2]. Allegations - The complaint alleges that Zenas BioPharma materially overstated its ability to fund operations with existing cash and expected net proceeds from the IPO, leading to false and misleading public statements [2]. Class Action Details - The class period for the lawsuit includes shareholders who purchased ZBIO securities during the time of the IPO registration statement and related prospectus [1]. - The deadline for shareholders to register for the class action and seek lead plaintiff status is June 16, 2025 [3]. Next Steps for Shareholders - Shareholders who register will be enrolled in a portfolio monitoring software to receive updates on the case's status [3]. - Participation in the case incurs no cost or obligation for shareholders [3]. Law Firm's Mission - The Gross Law Firm aims to protect investors' rights and ensure companies adhere to responsible business practices, seeking recovery for losses incurred due to misleading statements [4].

Core Viewpoint - A class action lawsuit has been filed against Zenas Biopharma, Inc. for alleged violations of federal securities laws related to misleading statements made during its IPO [1][2]. Group 1: Lawsuit Details - The lawsuit claims that Zenas Biopharma overstated the sustainability of its operations based on existing cash and expected IPO proceeds, leading to false and misleading public statements during the IPO period [2]. - Investors who purchased securities linked to the IPO on September 13, 2024, are encouraged to contact the law firm before June 16, 2025, to participate in the lawsuit [1][2]. Group 2: Law Firm Background - DJS Law Group specializes in securities class actions, corporate governance litigation, and M&A appraisals, focusing on enhancing investor returns through advocacy [3]. - The firm represents large hedge funds and alternative asset managers, emphasizing the value of litigation claims as significant assets [3].

Core Viewpoint - Rosen Law Firm is reminding investors of Zenas BioPharma, Inc. about the upcoming lead plaintiff deadline in a securities class action related to the company's IPO in September 2024 [1]. Group 1: Class Action Details - Investors who purchased Zenas BioPharma securities may be eligible for compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A class action lawsuit has already been filed, and interested parties must move the Court by June 16, 2025, to serve as lead plaintiff [3]. - The lawsuit alleges that the Registration Statement contained false or misleading statements regarding the company's financial situation and operational funding [5]. Group 2: Rosen Law Firm's Credentials - Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a successful track record in securities class actions [4]. - The firm has achieved significant settlements, including the largest securities class action settlement against a Chinese company at the time, and has consistently ranked highly in securities class action settlements since 2013 [4]. - In 2019, the firm secured over $438 million for investors, showcasing its capability in recovering funds for clients [4].

Core Viewpoint - Zenas BioPharma, Inc. is facing a class action lawsuit due to allegations of materially false and misleading statements regarding its financial status and operational funding capabilities during its initial public offering in September 2024 [2]. Group 1: Allegations - The complaint claims that Zenas BioPharma overstated the duration it could fund its operations with existing cash and expected net proceeds from the IPO [2]. - As a result of these misstatements, the public statements made by the defendants were deemed materially false and misleading throughout the relevant period [2]. Group 2: Class Action Details - The class period for the lawsuit includes shareholders who purchased ZBIO securities during the time of the IPO registration statement and related prospectus [1]. - Shareholders are encouraged to register for the class action by June 16, 2025, to potentially be appointed as lead plaintiffs [3]. - There is no cost or obligation for shareholders to participate in the case, and they will receive updates through a portfolio monitoring software [3]. Group 3: Law Firm Background - The Gross Law Firm is a nationally recognized class action law firm dedicated to protecting investors' rights against deceit and fraud [4]. - The firm aims to ensure companies adhere to responsible business practices and seeks recovery for investors who suffered losses due to misleading statements or omissions [4].

Core Viewpoint - Zenas BioPharma, Inc. is facing a class action lawsuit due to allegations of misleading information in its IPO registration statement, particularly regarding the funding timeline for its operations [1][3][4]. Group 1: Class Action Lawsuit Details - The class action lawsuit is titled Buathongsri v. Zenas BioPharma, Inc. and is pending in the District of Massachusetts [1]. - Investors who purchased Zenas BioPharma securities during its IPO on September 13, 2024, have until June 16, 2025, to seek lead plaintiff status [1][2]. - The lawsuit claims that Zenas BioPharma overstated its operational funding timeline, stating it could fund operations for 24 months instead of the actual 12 months disclosed later [3][4]. Group 2: Financial Impact - Zenas BioPharma sold over 13 million shares at $17.00 per share during its IPO [2]. - As of April 15, 2025, Zenas BioPharma's stock closed at $8.72, representing a decline of 48.7% from the IPO price [4]. Group 3: Legal Process and Representation - The Private Securities Litigation Reform Act of 1995 allows investors to seek lead plaintiff status if they have suffered losses related to the IPO [5]. - The lead plaintiff will represent the interests of all class members and can choose a law firm for litigation [5]. Group 4: About Robbins Geller - Robbins Geller Rudman & Dowd LLP is a prominent law firm specializing in securities fraud and shareholder litigation, having recovered over $2.5 billion for investors in 2024 alone [6]. - The firm has been ranked 1 in securing monetary relief for investors in securities class action cases for four out of the last five years [6].

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Zenas BioPharma, Inc. due to allegations of violations of federal securities laws related to misleading statements about the company's financial status and IPO funding [2][4]. Group 1: Legal Investigation - The law firm is encouraging investors who suffered losses in Zenas to contact them directly to discuss their legal options [1]. - A federal securities class action has been filed against Zenas, with a deadline of June 16, 2025, for investors to seek the role of lead plaintiff [2]. - The complaint alleges that Zenas materially overstated its ability to fund operations with existing cash and expected IPO proceeds, leading to misleading public statements [4]. Group 2: Class Action Details - The lead plaintiff in a class action is the investor with the largest financial interest who directs the litigation on behalf of the class [5]. - Any member of the class can move the court to serve as lead plaintiff or remain an absent class member without affecting their ability to share in any recovery [5]. Group 3: Additional Information - Faruqi & Faruqi encourages anyone with information regarding Zenas' conduct, including whistleblowers and former employees, to contact the firm [6].